BioCentury
ARTICLE | Clinical News

Biogen, Eisai discontinuing aducanumab studies in AD

March 21, 2019 12:30 PM UTC

Biogen and Eisai said aducanumab is unlikely to meet the primary endpoints of two Phase III trials to treat early Alzheimer's disease, joining a long list of failed mAbs against β amyloid and putting more pressure on Biogen to add to its Phase III pipeline.

The companies made the announcement Thursday based on an interim futility analysis and recommendation from an IDMC of its Phase III ENGAGE and EMERGE trials. The partners will discontinue the studies, as well as two other studies of the candidate...